Reimbursement/ Market Access

The reimbursement of your medical devices ensures the solvency of the market. Nevertheless, this decision remains the prerogative of each Member State of the EU.

WHITE-TILLET advises and assists you in:

  • The preparation of the market access strategy in France;
  • The critical-analysis of your clinical data (methodology, comparators, level of evidence)
  • The preparation of reimbursement files for France (medico-technical file for the CNEDiMTS, the economic efficiency file for the CEESP and the economic file for the CEPS);
  • The conventional negotiation for pricing with the CEPS;
  • The inscriptions on the LPP under generic description;
  • The preparation of platform files for Europe;
  • The analysis of national situations in the EU via our European network.

Rouard Ph et Tillet Y. The reimbursement of medical devices. Doses, February 2004.

Tillet Y. The re-examination process for reimbursement of generic medical devices in France. AMIPS Info 3ème et 4ème Trim 2006;74:90-94.

Rath-Lavialle A., Tillet Y. La place des données cliniques dans l’évaluation de la conformité ou de la prise en charge des dispositifs médicaux. La Gazette de l’AFAR; 89 (Octobre 2015): 16-22.

Contact

+33 1 60 08 43 85
+33 1 60 08 00 22

24 Rue Gambetta 77400 LAGNY-SUR-MARNE, France